Skip to main content

Safety and Side Effects of Psychotropic Medications, Volume II

Cover image for Research Topic "Safety and Side Effects of Psychotropic Medications, Volume II"
61kviews
Editorial06 December 2023
Editorial: Safety and side effects of psychotropic medications, volume II

Keywords: Adverse drug reaction (ADR); Adverse effects; Mental disorders; Mental health; Psychiatry; Psychopharmacology; Safety; Tolerability.Word count: 1,047/1,000The safety and tolerability of psychotropic medications have always been a significant concern within the realm of mental health treatment (1,2). Over recent years, there has been a noticeable uptick in the collection of evidence-based data and dedicated research endeavors aimed at gaining a more comprehensive understanding of the advantages and drawbacks tied to these medications (3,4). This surge in empirical research has empowered healthcare providers to make more informed decisions when prescribing psychotropic drugs and personalizing treatment plans to meet each patient's unique needs (5,6). Furthermore, research has been actively engaged in a collaborative effort to devise new strategies and medications boasting enhanced safety profiles and reduced adverse drug reactions (ADRs) (7,8). As the field continually evolves, the focus on patient safety and the fine-tuning of psychotropic treatments remains an overarching priority, with the ultimate goal of improving mental health outcomes for individuals worldwide (9,10).Therefore, following the first volume of this research topic (11), our objective was to compile articles that delve into the safety and ADRs of psychotropic medications. We invited contributions from all sources that could potentially provide fresh insights and evidence to this critical subject matter.Akbarzadeh and colleagues evaluated the effect of adding an extract of the plant Alpinia galanga, known for enhancing sexual function, to the treatment of adult males taking selective serotonin reuptake inhibitors (SSRIs) with the goal to improve SSRI-induced erectile dysfunction (12). They designed a triple-blind randomized clinical trial involving 60 adult male participants on SSRIs, receiving 500mg of Alpinia galanga extract or placebo, and adding Alpinia galanga to the SSRIs treatment seems to be a promising approach to alleviate the SSRI-related sexual dysfunction in male. Kimura et al. conducted a systematic review aimed to assess the heart safety of escitalopram in comparison to a placebo for patients with underlying cardiovascular issues (13). The analysis included 5 randomized controlled trials with a total of 773 participants. Escitalopram did not significantly increase the risk of major adverse cardiovascular events, medication discontinuation, or QTc prolongation when compared to a placebo in patients with underlying cardiovascular disease.Udo Bonnett commented on a previous article (14) about the more attention needed in prescribing SSRIs during COVID-19 adding interesting discussion points (15). In particular, in the light of the increased SSRIs prescription trend in coronavirus infections (i.e., fluvoxamine) it should also be considered the potential occurrence of an anxiety/jitteriness syndrome (AJS, also known as "activation syndrome") as a common ADR of SSRIs. Therefore, the AJS might be mistakenly identified as neuropsychiatric or gastrointestinal symptoms of COVID-19 or as a worsening of an existing COVID-19 condition.The team led by Xu conducted a systematic review between the citalopram plasma concentration and treatment outcomes in depression (16). The review did not establish a clear correlation between citalopram plasma concentration and clinical or cost-related outcomes, but there was some limited evidence hinting at improved treatment effectiveness in patients with plasma concentrations above 50 or 53 ng/mL.Xiang and colleagues aimed to examine the impact of a Chinese policy implemented on September 1, 2019, which classified oxycodone/acetaminophen as a psychotropic medicine due to its history of misuse, with the goal to regulate its use in medical institutions (17). Through a prescription data analysis from five tertiary hospitals in Xi'an city over 42 months, authors concluded that the stricter regulation of oxycodone/acetaminophen helped reduce the risk of misuse among short-term drug users.In another retrospective analysis run in a long-term hospital with chronic schizophrenia patients with co-existing type 2 diabetes who were prescribed olanzapine or risperidone as primary antipsychotic medication with or without co-prescribing aripiprazole (18). Liu et al. compared various parameters between the two groups and assessed the factors influencing prolactin levels. The results showed that the co-aripirazole group had significantly higher levels of fasting blood glucose, blood uric acid, cholesterol, and triglycerides, but there was no difference in prolactin levels between the two groups.An EUDRAVigilance dataset screening led by Cicala aimed to provide a more comprehensive understanding of the safety and tolerability of paliperidone palmitate (PP) using real-world pharmacovigilance data (19). This analysis of 8,152 reports suggested that the safety and tolerability profiles of PP are generally consistent with other second generation long-acting anitpychotics, with only higher probabilities of reporting specific ADRs in PP-related reports, particularly related to sexual dysfunctions, haemodynamic edema, effusions, fluid overload, and fertility disorders. Hamasaki and Yanai conducted a retrospective cohort study with the aim to investigate the impact of psychotropic drug use on handgrip strength and hospitalization in individuals with type 2 diabetes (21). Authors concluded that the use of psychotropic drugs may increase the likelihood of repeated hospitalizations among patients with type 2 diabetes. Morevoer, the study suggests that skeletal muscle strength, as reflected by handgrip strength, may have a role in reducing the risk of hospitalization in individuals receiving psychotropic drug treatment.The study by Kyung-In investigated the gender differences in ADRs associated with zolpidem, with data from the Korea voluntary adverse drug events reporting system (KAERS) for the years 2015-2019 (22). Of all the ADRs with gender differences in reporting risk, somnambulism stood out as the most consistent and substantial difference. This suggests that women may have a higher susceptibility to somnambulism, which is a potentially serious adverse effect associated with zolpidem.While psychopharmacological research has already generated a substantial amount of data on numerous facets, we contend that the clinical perspectives presented in these articles offer a practical and innovative viewpoint that could lead to a more precise allocation of resources, piquing the interest of both clinicians and researchers (23,24). In light of the psychopharmacological trends discussed in the collected papers, it is crucial to underscore the pressing need for a deeper exploration of ADRs associated with psychotropic medications. The findings compiled in this research topic do not discourage the use of psychotropic drugs but rather advocate for their thoughtful and informed prescription.

2,528 views

2 citations

Cardiovascular adverse reactions associated with escitalopram in patients with underlying cardiovascular diseases: a systematic review and meta-analysis
Background: Despite the anticipated efficacy of escitalopram in treating depression and anxiety in individuals with preexisting cardiovascular conditions, persistent concerns regarding its adverse effects have emerged. In this systematic review, we aimed to evaluate the cardiovascular safety profile of escitalopram compared with that of placebo in patients with underlying cardiovascular disease.We used a predefined search strategy in PubMed, Cochrane Central Register of Controlled Trials, Embase, International Clinical Trials Registry Platform, and ClinicalTrials.gov to identify studies evaluating adverse cardiovascular reactions to escitalopram in patients with underlying cardiovascular disease. Randomized controlled trials (RCTs) that provided results on cardiovascular safety outcomes were included. Two independent reviewers screened the abstracts and full texts of the individual studies. The risk of bias was assessed using version 2 of the Cochrane risk-of-bias tool for randomized trials. The certainty of evidence was assessed using the Grading of Recommendations, Assessment, Development, and Evaluation approach.Results: The primary outcomes were the frequency of major adverse cardiovascular events (MACE), QTc prolongation, and discontinuation of study medication. We identified 5 RCTs with 773 participants who met the inclusion criteria. Escitalopram was not associated with significantly This is a provisional file, not the final typeset article increased risk of MACE (risk ratio [RR] = 1.85; 95% confidence interval [CI] 0.80 to 4.26; I 2 0%; 5 RCTs; n = 773, moderate certainty of evidence), discontinuation of study medication (RR = 1.03; 95% CI 0.84 to 1.26; I 2 0%; 5 RCTs; n = 773, low certainty of evidence), and QTc prolongation (RR = 1.20; 95% CI 0.76 to 1.90; I 2 0%; 4 RCTs; n = 646, low certainty of evidence).Escitalopram does not significantly increase the risk of cardiovascular adverse reactions compared with placebo in patients with underlying cardiovascular disease. However, the presence of wide CIs and the limited number of included studies highlight the need for further studies with larger sample sizes to enhance the precision and reliability of these findings.

26,530 views

3 citations

Objective SSRIs are considered the first line in the medical treatment of depression and anxiety disorders. One of their most common side effects, sexual dysfunction, has led many patients to discontinuing their medication and treatment course. Alpinia galanga, a plant from the ginger family, has been shown to enhance androgenic activity and sexual function. This study aimed to assess whether the addition of Alpinia galanga extract to the treatment regimen of adult males consuming SSRIs can improve SSRI-induced erectile dysfunction. Materials and Methods This triple-blind randomized clinical trial was conducted on 60 adult males who were being treated with SSRIs at the time of the study. The participants were divided into two groups, a group of 30 people receiving 500 milligrams of Alpinia galanga extract, and a group of 30 subjects receiving placebo. The population were re-assessed on week 2 and week 4 of the study using the international index of erectile function (IIEF), the Beck Depression Inventory, and the Beck Anxiety Inventory. In all the tests, a p-value of 0.05 was considered as the cut-off for significance. Results At the beginning of the study, the IIEF score of the placebo group and the intervention group were 10.6±3.8 and 11.2±4.8, respectively, which were not significantly different (p-value=0.577). By week 4 of the study, the IIEF scores of the control group and the Alpinia galanga group had increased to 13.7±4.3 and 17.4±3.7 respectively, which demonstrates a remarkably larger increase in the group receiving Alpinia galanga extract in comparison to the placebo group (p-value<0.001). Conclusion In this study, the effect of the addition of Alpinia galanga extract to the treatment regimen of male patients using SSRIs on the sexual dysfunction experienced by this group has been promising. Similar results, if proven, can aid both patients and clinicians in making and following better treatment plans with more pleasant outcomes.

12,366 views

10 citations

ORIGINAL RESEARCH
16 March 2023
Evaluation of the effect of managing oxycodone/acetaminophen as a psychotropic medicine: An interrupted time-series study
Cheng Xiang, 6 more and Kanghuai Zhang

3,474 views

1 citations